Creating engaging, compliant risk management support materials
The Challenge
Our client asked Ashfield MedComms to help their risk-management planning by producing educational manuals targeted at different stakeholder groups in line with guideline recommendations. The materials were in support of the commercialisation of a new chimeric antigen receptor T-cell (CAR-T) therapy for treating multiple myeloma.
The Approach
The team began by scheduling a series of advisory board meetings with each stakeholder group to identify specific content. Stakeholders included CAR-T physicians, referral physicians, pharmacists, nurses and patients.
Complex information on CAR-T therapy was then shaped and presented in a creative and engaging way, including clear messaging, graphics and icons to ensure accessibility, compliance and maximum impact. In particular, the Ashfield MedComms patient engagement team ensured the patient guide had the right level of messaging for the target audience.
The materials were then reviewed to ensure they were fit for European Medicines Agency approval.
The Results
The manuals were a success and now another is being developed specifically for caregivers. The client has also asked Ashfield MedComms to adapt the information for interactive online platforms for HCPs and patients.
Discover more about EmerGENE
EmerGENE is the first multidisciplinary, global network of experts from across Ashfield, all passionately focused on the success of your cell and gene therapy.